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 In spite of the general decline in cervical cancer incidence and the highly preventable 
nature of this cancer, new cases and deaths are recorded annually in Maryland and in 
other parts of the United States. Using the cancer care continuum and the Human 
Papillomavirus (HPV) carcinogenesis process as guiding frameworks, this research 
evaluated the prevention and control of invasive cervical cancer (ICC) among the 
subgroups at highest risk for disease.  
Methods 
 In Aim 1 using registry data we evaluated space-time variation in ICC incidence over a 
10-year period at the county level within the state of Maryland. For Aim 2 we 
longitudinally assessed utilization and determinants of Pap testing among women living 
with HIV (WLWH) seen at Johns Hopkins Hospital over a 10-year period. Finally, in 
Aim 3 using data from HIV positive and high-risk HIV negative women enrolled in the 
Women’s Interagency Health Study (WIHS) cohort, we examined the determinants and 
risk conferred by prevalent type-specific cervical HPV infections on the acquisition of  
oral HPV infections.  
Results  
Aim 1- The overall average annual crude and adjusted state ICC rate between 2003-2012 
for Maryland was 7.3 per 100,000. Upon adjusting for contextual differences including 
median income, age and Pap testing rates at the county level, the average annual adjusted 
ICC incidence rate in Maryland for this period was 9.2 per 100,000. Within this period, 
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2003-2012, we identified some clusters with significantly different ICC incidence rates 
than rates observed in the rest of the state. These included both clusters of significantly 
lower and higher than expected incidence rates (p-value ≤0.05). Two of the 3 significant 
clusters of higher than expected ICC incidence rates identified occurred in a more recent 
time period, 2009-2012. The third significant cluster of high rates was observed in an 
earlier period, 2005-2008. 
Aim 2- Our findings showed that although most WLWH (79%) in clinical care receive 
Pap testing, some women (21%) are not screened and others (5%) consistently receive 
Pap testing at intervals longer than recommended. WLWH with a decreased likelihood of 
screening included older women, injection drug users, white women and those who had 
lived for a longer time with HIV.  
Aim 3- Factors associated with an increased risk of incident oral HPV infection included 
a recent history of sexual activity with either a male (adjusted hazard (aHR)=2.47, 
95%CI: 1.02-6.01) or female partner (aHR=2.79, 95%CI: 1.14, 6.79) as well as a recent 
history of performing oral sex (aHR=1.75, 95%CI: 1.16, 2.62). No association was 
observed with type-specific cervical HPV infection, age, alcohol or condom use during 
oral sex.  
Conclusions  
Although ICC rates have declined over time, there are still some counties experiencing an 
anomalously high ICC incidence rate. The recent clusters of high ICC incidence rates 
identified need to be prioritized and investigated further, while the clusters of low 
incidence rates identified may represent areas of successful prevention and control within 
the state of Maryland. The determinants of Pap testing identified in Aim 2 present 
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potential targets in an urban HIV care setting for closer monitoring and directed 
interventions to improve Pap test adherence among WLWH. Findings for Aim3 suggest 
that having a prevalent cervical HPV infection does not increase the risk of an incident 
type-specific oral HPV infection; however, sexual activity remains a significant risk 
factor for acquiring oral HPV infections.  
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The development and introduction of Pap testing as a secondary prevention tool for 
invasive cervical cancer (ICC) has led to dramatic declines in national ICC rates over the 
past few decades [1-3]. In spite of this decline, and a direct annual cost of about $1.55 
billion expended on screening alone [4-6], an estimated 12,360 new ICC cases and 4,000 
ICC deaths occur annually within the United States. The continued presence of ICC 
within the United States is said to be largely due to failures across the cancer care 
continuum, which give rise to missed opportunities for effective prevention and control 
among the subgroups at highest risk [7-9]. In addition, the burden of ICC is uneven 
across subgroups within the United States population and the literature identifies racial 
minorities and middle aged women as being at highest risk for disease [10]. This 
definition however is not specific; therefore, expanding the current evidence base on the 
characteristics of the subgroups at highest risk, beyond measures of race and age, may 
facilitate a more efficient approach to prevention and control among the women most 
likely to develop ICC.  
Presently at the local level epidemiologic data on disease trends and the relevant factors 
associated with variation in ICC incidence across smaller geographic units is scant [9,11]. 
In addition, previous examinations of ICC incidence have not assessed the role of 
contextual factors on any observed variation in disease incidence overtime. This 
limitation in the available evidence base, in part contributes to the one-size fits all 
approach to ICC prevention and control that fails to adequately address the needs of the 
subgroups at highest risk. Thus, identifying the areas with significantly higher or lower 
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ICC incidence rates, after accounting for contextual differences, will provide additional 
data for efficient prioritization of ICC needs.   
Although routine cervical cancer screening is highly effective and saves lives, over 50% 
of ICC cases recorded within the United States occur among women who were rarely or 
never screened for ICC [12-15]. Even when in care, some high-risk women are either 
never screened or under-screened (i.e. receive no screening or less screening than 
recommended) for cervical pre-cancers and cancers [16-23]. Included in this group of 
high-risk women are women living with HIV (WLWH), for whom screening is extremely 
important given their elevated risk of ICC [24]. However, in the current treatment era, 
there have been limited longitudinal evaluations of utilization of cervical cancer 
screening services among WLWH. Cross-sectional studies and relatively short 
longitudinal evaluations of screening may not adequately reflect screening patterns 
overtime. Therefore, assessing trends in cervical cancer screening and evaluating 
potential predictors of utilization using longitudinal follow-up over long periods of time 
may be a more informative approach to understanding screening among WLWH. 
Human Papillomavirus (HPV) is causally linked to both ICC and some oropharyngeal 
cancers and although sexual behavior greatly influence the risk of HPV infections at the 
two sites, the association between type-specific infections at the two anatomic sites is not 
well understood [25]. There are unanswered questions about the potential risk posed by 
prevalent type-specific cervical HPV infections on the subsequent risk of acquiring the 
same HPV types orally through autoinoculation. Assessing the relationship between 
cervical and oral HPV infections will add relevant data to the existing literature on the 
natural history of oral HPV infections. This is especially important given the relatively 
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less well understood natural history of oral HPV infections and the recent overall increase 
in the incidence of HPV associated oropharyngeal cancers [26]. In addition, 
understanding this relationship might have implications for WLWH, who are known to 
have a fivefold increased risk of acquiring HPV cervically and are also more susceptible 
to oral HPV infections.  
Research Aims 
Given the current challenges outlined above in the prevention of HPV associated 
malignancies among high-risk women, the overarching purpose of this research is to 
generate additional evidence to enhance effective prevention and control among the 
subgroups at highest risk. Specifically, the aims of this research are: 
1. To explore and describe the space-time variation in ICC incidence by county 
within the state of Maryland from 2003-2012. (Chapter 2) 
Hypothesis: Although national and Maryland state ICC rates have generally 
declined, this decrease is not uniform across all counties. Incidence has varied 
significantly over time and this variation is partly explained by differences in county 
characteristics including sociodemographic and health care seeking behavior.  
2. To longitudinally describe utilization of Pap testing and assess factors associated 
with utilization among WLWH enrolled in clinical care at the Moore Clinic of 
Johns Hopkins Hospital from 2005-2014. (Chapter 3) 
Hypothesis: Even when enrolled in clinical care, some WLWH do not receive 
routine Pap testing and others are under-screened. This is associated with clinical and 
sociodemographic characteristics of WLWH including age, race, type of health 
insurance and CD4 count.   
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3. To assess the determinants and risk conferred by prevalent type-specific cervical 
HPV infections on the subsequent acquisition of type-specific oral HPV 
infections. (Chapter 4) 
Hypothesis: Women with prevalent type-specific cervical HPV infections are at 
increased risk of acquiring the same HPV types orally.  
 
LITERATURE REVIEW 
Cervical Cancer and HPV Infections  
ICC is caused by HPV infections, which is the most common sexually transmitted 
infection within the United States [27,28]. Persistent HPV infections, specifically that of 
oncogenic subtypes, increase the risk of cervical precancers that often progress to ICC if 
left untreated [29,30]. Aside ICC, the HPV virus has been etiologically linked to other 
female cancers including some oropharyngeal cancers, vaginal, vulvar and anal cancers.  
Burden of ICC 
Compared to other cancers the national burden of ICC is relatively lower and it ranks as 
the 13th leading cause of cancer cases among females within the United States [31]. 
Currently the annual incidence rate of ICC in the United States is 7 cases per 100,000 and 
the mortality rate for ICC is 2 per 100,00 [32,1]. However in spite of the low disease 
burden, estimates indicate that in 2010 alone about 100, 000 years of life were lost to ICC 
[33] and by 2020 the total value of lives lost due to cervical cancer will be $13.5 billion 
[34]. This tremendous cost associated with ICC is largely due to the high disease burden 
recorded among middle-aged women within the United States. Aside the financial and 
human cost of disease there are substantial negative societal and familial repercussions 
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associated with an ICC diagnosis or death and this is especially more pronounced for the 
subgroups at highest risk of disease.  
Disparities In ICC Burden  
There are known disparities in ICC incidence and mortality within the United States and 
some high-risk subgroups have been documented to have an incidence rate as high as 40 
per 100,000 population [10]. . This extremely high incidence is about six-times the 
national average and is similar to rates observed in sub-Saharan Africa, which has the 
highest burden of ICC globally, with very limited or no formalized ICC prevention and 
control programs. Thus, the endemic nature and disparate burden of ICC within the US is 
concerning especially given that ICC is highly preventable and ICC deaths are highly 
avoidable, at least theoretically, given the availability of effective prevention and 
treatment strategies. 
Beyond Race: Characterizing And Defining Subgroups At Highest Risk 
Mainly on account of the high burden among racial minorities, the current literature often 
characterizes ICC disparities mainly or solely by race. However, race is unlikely to be the 
sole factor associated with the uneven disease burden across various subgroups within the 
United States [35]. For example, although white women have the lowest ICC burden 
nationally, white women living in rural underserved Appalachia have been documented 
to have incidence rates that are at least 40% higher than the national average [36-38].  
 Other social and biological factors including health insurance status, level of education, 
income, competing healthy priorities, comorbidities, geographic location (neighborhood 
socioeconomic status, degree of urbanization and adjacency to a large metropolitan area) 
as well as the general health status of women maybe determinants of disease risk and 
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distribution [39,35]. These other factors are also likely to influence care seeking and 
utilization. Thus, going beyond race to revise the current definition of the subgroups at 
highest risk is important as it may potentially enhance the efficiency of current programs 
in targeting the groups with the greatest ICC needs.  
Addressing ICC As A National Public Health Priority 
Over the years there have been calls for the expansion of the existing evidence base on 
the best approaches to address ICC, especially among high-risk groups, with the long-
term goal of eliminating this highly preventable cancer from the United States [40,9,41]. 
One such calls came from the United States Preventive Services Task Force (USPSTF) in 
2012, which identified the continued annual recording of ICC cases and deaths within the 
United States as a public health challenge [9]. The USPSTF listed ICC as one of six high 
priority areas for targeted action and highlighted the limited scientific evidence on 
effective strategies for implementing programs among high-risk groups, as a major 
barrier to effective ICC control [9]. The Task Force specifically stated that in order to 
further reduce the current burden “more research is needed to understand what factors are 
associated with inadequate screening and how to help deliver the best screening and 
treatment” to the subpopulations with the highest disease burden [9].  
In addition, the Healthy People 2020 program has listed reducing the number of ICC 
cases and deaths as one of its cancer specific objectives [40]. The program proposes to 
assess screening adherence and ICC incidence as a means to promote evidence based 
screening and to monitor the success of ICC programs [40].  Aside these national 
programs, some states including Maryland, North and South Carolina, Massachusetts, 
Alabama, Texas and Utah recognize ICC as a public health priority [42]. These states aim 
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to eliminate ICC by increasing the proportion of eligible females screened, the proportion 
appropriately followed-up after a positive screening result and the proportion vaccinated 
against HPV infections [42].  
National ICC Programs  
The literature shows that for the general population in care, most of the documented ICC 
cases occurred among women who were rarely or never screened in the years prior to 
diagnosis. These reported ICC cases, though having been rarely or never screened for 
cervical precancers and cancers, did access other health care services on a regular basis in 
the years prior to diagnosis [12,43]. Hence to address ICC, the Centers For Disease 
Control supported by an act of Congress, set up the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP) in 1990 [44]. The NBCCEDP serves low-income, 
uninsured, and underserved women by providing access to timely breast and cervical 
cancer screening and diagnostic services [44]. In addition all states empowered by the 
Breast and Cervical Cancer Prevention Act, have the discretionary power to offer women 
diagnosed with precancers or cancer under the NBCCEDP, access to treatment services 
through state Medicaid programs [44-46].  
Even with the NBCCEDP, high-risk groups encounter enormous barriers in accessing 
services. Overall, less than 90% of those eligible to receive preventive services under 
NBCCEDP have access to it[47]. While about 60% of women 18-64 years who are 
eligible under the NBCCEDP, get screened outside of the program and the remaining 
33.3% do not receive screening as recommended [47]. Barriers documented to impede 
access at the national level, for the entire program, include geographic barriers, high cost 
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of copays, limited health literacy and self-efficacy, competing health and personal 
priorities as well as suboptimal care provided within the cancer continuum. 
ICC Prevention and Control in Maryland 
The state of Maryland currently has ICC rates similar to the national average and has 
outlined objectives within its current cancer control plan to address the disparities that 
drive ICC persistence [48]. In this plan ICC is specifically listed as one of the cancers for 
increased policy focus and targeted state action. The state as part of its NBCCEDP offers 
free cervical cancer screening and treatment services. Yet in spite of this program, ICC is 
still persistent in Maryland and new ICC cases and deaths are recorded annually. A recent 
assessment of the quality of ICC treatment received by patients diagnosed in Maryland 
showed significant differences in the appropriateness and type of care received by racial 
minority groups within the state [49]. Thus, it is unclear if the current state program is 
able to identify and deliver interventions to the sub-groups and areas with the greatest 
ICC burden.  
Enhancing The Effectiveness of Current Programs Using Spatial and Temporal 
Analysis   
Currently there is limited available data at the local level within states, on the rates and 
factors associated with ICC incidence and mortality, especially among high-risk sub-
groups [50]. Further, most of the available data and estimates are based on large aerial 
units such at the state, regional and national levels, which are likely to be heterogeneous 
in terms of their composition and risk profile of residents. Additionally, the combined 
effect of contextual factors including socioeconomic characteristics, overall health status, 
screening rates as well as race and how they might contribute to ICC incidence has not 
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been extensively assessed. These data limitations in part accounts for the blanket one-size 
fits all approach to the delivery of ICC interventions [50], where programs often fail to 
account for underlying differences in risk profiles especially among groups and areas at 
highest risk. 
Spatial epidemiology presents a formal way to separate signal from noise in examinations 
of trends in incidence across geographic units and over time while accounting for 
relevant factors that might influence any observed variation [51-54]. Tools from the field 
of spatial epidemiology, for example a cluster detection approach, allows for the 
objective identification and visualization of geographic areas of anomalous cancer 
incidence in space and time [55]. Further; areas of significantly high or low cancer 
incidence identified using spatial epidemiology can inform efficient redistribution of 
cancer prevention and control efforts [56,33]. Estimating disease rates at aerial units 
smaller than the state level (e.g. county or census tract level) might improve the 
efficiency and effective targeting of the subpopulations at highest risk. This will ensure 
that the available effective prevention and treatment strategies for ICC are delivered and 
utilized in the most impactful cost-effective manner. 
HIV Patients As A High-Risk Group For ICC 
Women living with HIV (WLWH) are at an increased risk of developing ICC and this is 
as a result of their increased susceptibility to HPV infections and their decreased ability 
to clear HPV infections once acquired [57]. Among WLWH, ICC is the most prevalent 
AIDS associated malignancy and an ICC diagnosis is considered as AIDS defining [58]. 
Compared to the general population, WLWH have an increased risk of developing 
cervical precancers and cancers [59,60]. In addition, the rate of progression from one 
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stage of the HPV carcinogenesis process to the next is much faster among WLWH 
[60,61]. Also for WLWH, ICC treatment failure rates are known to be higher and 
survival rates are much lower compared to women in the general population [62]. 
ICC Screening Among WLWH 
The subgroups at highest risk of ICC, often have limited access to routine screening and 
prevention within the cancer care continuum and account for over 60% of all ICC cases 
[63,7]. By virtue of their increased risk, prior to 2015, it was recommended that WLWH 
receive cervical cancer screening twice, at six-months intervals, within the first year of 
diagnosis and if both results were normal, cervical cancer screening could then be 
administered on a yearly thereafter [64,65]. More recently these guidelines for WLWH 
have been updated to suggest a three-year follow-up interval among women with 3 
consecutive normal Pap test results [66]. Notwithstanding these guidelines, some studies 
have shown about 25% of HIV positive women in care do not receive cervical cancer 
screening on a routine basis, as is recommended [61]. However, these previous studies 
have largely been cross-sectional in nature, relied on self-reports, or followed WLWH in 
clinical care for a relatively short period of time [16-23]. Therefore, longitudinally 
evaluating cervical cancer screening and the factors associated with under utilization of 
screening will provide relevant for improving screening adherence among WLWH.  
Autoinoculation As A Mechanism For Acquiring Type-Specific HPV Infections 
Although HPV infections are transmitted primarily through sexual contact, there is some 
potential for transmission through non-penetrative sexual contact through masturbation 
and infection may also be transmitted through autoinoculation [67,68]. Autoinoculation 
refers to the “transmission of a prevalent HPV infection between the genitals, anal canal, 
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oral cavity or hands of an infected individual during routine genital self-handling” 
[67,69]. Plausibility for autoinoculation is supported by evidence from a cohort of newly 
sexually active females, where HPV DNA was detected in the fingertips of 30% of 
women with prevalent cervical infections of at least one HPV type [68]. The concordance 
rate between types detected in cervical and fingertip samples was 60% and over 90% of 
these had the same variants detected in both cervical and fingertip samples [68]. 
Suggesting outside of sexual transmission, transfer of infections between anatomic sites 
such as the cervix and oropharynx may occur through deposition of HPV DNA on the 
fingertips of individuals with prevalent infections.  
Oral HPV Infections  
In the US, 40-80% of oropharyngeal cancers are associated with HPV  [70-72]. Oral 
acquisition and subsequent persistence of some high-risk types elevates the risk of HPV 
associated oropharyngeal cancers [73,74]. This is especially true for HPV 16 infections, 
which aside being the main HPV type associated oropharyngeal cancers, has a longer 
time to oral clearance compared to other high-risk HPV types [25] . For these HPV 
associated oropharyngeal cancers, HPV 16 is the main oncogenic subtype and is causally 
linked to about 90% of HPV associated oropharyngeal cancers and 60% of all ICC [70-
72]. However, in spite of the common etiologic link between cancers at these two 
anatomic sites, the relationship between HPV infections at both sites is not well 
elucidated. Further, unlike cervical HPV infection, the natural history of oral HPV 
infection is relatively less well understood [25].  
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Correlation Between Type-Specific Cervical and Oral HPV Infections  
A cross-sectional examination of the correlation between prevalent oral and cervical HPV 
infections, compared to women without a cervical infection, the prevalence of oral HPV 
infections among women with cervical HPV infections was significantly higher (25.5% 
versus 7.9% p-value= 0.002) [75]. Further examination of type-specific concordance after 
correcting for chance agreement, demonstrated 6.3% type concordance between 
infections at the two anatomic sites [75]. A more recent study using national survey data 
in the United States, observed a fivefold higher prevalence of oral HPV infections among 
women with cervical infections when compared to women without a cervical HPV 
infection [76]. Using data from 10 studies a meta-analysis of correlation by type between 
cervical and oral HPV infections reported a pooled prevalence of 18.% for oral HPV 
infections among women with a cervical infection [77]. For this study the type-specific 
concordance rate between cervical and oral HPV infections was 46.8% and 15.6%, 
respectively for WLWH and HIV negative women [77].  
Although these previous studies suggest an increased risk of oral HPV infection among 
women with a cervical infection, there are unanswered questions about the relationship 
between cervical and oral HPV infections. Due to the mainly cross-sectional nature of 
these previous assessments [78,75,79] the temporal sequence of oral acquisition could not 
be explored. Further these studies were severely limited in the sample size utilized. 
Evaluating the relationship between type-specific cervical and oral HPV infections, using 
data collected prospectively, will add to the current literature on the role played by 




The theoretical framework guiding this research (Figure1) incorporates the HPV 
carcinogenesis process into a modified cancer care continuum framework, beginning with 
primary prevention of HPV malignancies and ending with diagnosis/treatment. The 
framework recognizes that the development of disease outcomes during the  
carcinogenesis process including the acquisition of HPV infections, its persistence or the 
development of invasive disease, is influenced by the underlying biology of an individual 
[6]. 
Figure 1-1. Conceptual framework of research study 
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However, aside this underlying biology, individual patient level factors determine 
interaction with the care continuum and influence the level of access to cancer care and 
by extension eventual outcomes with respect to HPV carcinogenesis [8]. Among high-
risk individuals level factors that influence interaction with the cancer continuum include 
age, care-seeking behaviors, socioeconomic status, race and geographic location.  
Drawing from the social ecological model, the framework presented above also 
recognizes that aside individual level factors, factors operating at higher levels might also 
influence interaction of high-risk patients with the care continuum. These higher level 
factors include institutional level factors i.e. provider and community level factors as well 
as national, states and local level policies and programs [80].  
Acting either independently or in concert with individual patient characteristics, these 
higher levels may either directly or indirectly influence the frequency and nature of 
failures experienced within the cancer care continuum [8]. Therefore, this research seeks 
to understand the individual level and community level characteristics of high-risk 
subgroups that promote the development of negative outcomes along the HPV 
carcinogenesis process.  Characterizing these subgroups may potentially improve 
targeting of available prevention and control efforts and inform the development of 
appropriate interventions to further accelerate the decline of the current disease burden 
within the United States.  
 
 16 
CHAPTER 2: SPATIAL EPIDEMIOLOGY 
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A Spatiotemporal Analysis Of Invasive Cervical Cancer Incidence In The State Of 







Purpose: Invasive cervical cancer (ICC) rates have tremendously declined in the United 
States, yet new cases consistently occur in Maryland and throughout the United States. 
We hypothesized that although rates have generally declined, this decline is uneven 
across counties and over time. 
Methods: Using a space-time cluster detection analysis we evaluated clusters of high and 
low incidence at the county level within the state of Maryland.  
Results: The most likely cluster observed was a cluster of low incidence, which included 
6 counties in eastern Maryland for the period 2009-2012. A secondary cluster of low 
rates, comprising 2 metropolitan counties in northern Maryland, was also observed for 
the period 2009-2012. 
Two of the 3 clusters of high ICC rates occurred 2009-2012. This included the large 
metropolitan area of Baltimore City and another cluster of high rates in Frederick County, 
in rural western Maryland. The third cluster of high rates was observed 2005-2008, 
comprising one rural and one metropolitan county in western Maryland. 
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Conclusion: In recent periods, some counties in Maryland have experienced 
anomalously high or low ICC incidence. Clusters of high incidence need to be prioritized 






Over the last few decades, rates of invasive cervical cancer (ICC) rates in the United 
States (US) have steadily declined due to the introduction and use of Pap screening as a 
screening test for early detection of ICC and its associated precancerous lesions [81,82]. 
In spite of this decline, 12,360 new ICC cases are diagnosed annually of which about 
4,000 go on to die [83]  and in 2010 alone about 100, 000 years of life were lost to ICC 
[33] . The continued presence of ICC in the US is in part due to underlying inequalities 
and disparities in access to screening and treatment services, which occur as a result of 
economic and knowledge-related barriers [84,82] that often vary based on the community 
in which a woman lives. Nationally, there are known disparities in ICC incidence, with 
racial minorities, low income and rural populations having the highest disease burden 
[85-90]. For example, ICC incidence rate among older black women is twice the rate 
among white women of the same age even after accounting for differences in 
hysterectomy rates [10]. 
Current ICC incidence in the state of Maryland reflects national rates and similar to 
national trends, every year there continues to be women diagnosed with ICC and some 
women dying from ICC in Maryland [49]. Therefore given the availability of effective 
screening tests and treatment, which makes ICC highly preventable and treatable, the 
state of Maryland identified ICC as one of its seven high priority cancers for targeted 
action [91,92]. As part of its ongoing efforts to address ICC, the state offers low-income, 
uninsured, and underserved women free ICC screening, diagnosis and treatment services 
through the Centers for Disease Control’s National Breast and Cervical Cancer Early 
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Detection Program (NBCCEDP) [93]. However, even with the NBCCEDP program, 
prevalence of Pap screening remains lower among some key populations including 
uninsured women and women without a primary care provider [94]. Further, research in 
Maryland suggests that compared to white women, black women have significantly 
higher ICC incidence and mortality rates [91]. In addition, black women are more likely 
to present with more advanced cases of ICC and are less likely to receive appropriate 
treatment given the stage of disease [49].  
Using a space-time model, a previous examination of variation in ICC incidence by 
counties in the United States, reported elevated rates in counties with a low prevalence of 
cervical cancer screening and a higher incidence for some racial minority groups 
including non-Hispanic blacks, American Indians and Hispanic women [33]. This study 
however, was conducted for a relative short period (2000-2003) and provided limited 
information about specific areas of elevated rates. In addition, it did not assess the 
significance of the observed increase in ICC incidence in some geographic areas, 
including Maryland.  
Indeed previous Maryland state cancer reports have described both overall ICC incidence 
across Maryland and by counties within the state [91,95]. These reports however, did not 
examine the space-time variation in ICC incidence across Maryland. Further, previous 
studies did not assess the combined effect of contextual factors at the county level, (such 
as socioeconomic characteristics, overall health status, screening rates, and racial 
composition) and how these factors might influence observed variations in ICC. Hence, 
this current study assessed variation in ICC incidence by counties in the state of 
Maryland over a 10-year period. We hypothesized that although national and Maryland 
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state rates have generally declined overtime, after accounting for differences in relevant 
county characteristics, some counties have experienced an ICC incidence that is either 
significantly higher or lower than expected.
 
METHODS 
Data and Study Population 
Data on ICC cases diagnosed between January 2003 and December 2012 were obtained 
from the Maryland Cancer Registry. For each case, data from the Cancer Registry 
included information on county of residence at diagnosis, age at diagnosis, country and 
state of birth for those born in the US, marital status, type of reporting source for case 
diagnosis and/or death, race, grade, metastasis, insurance status and diagnostic 
confirmation. The analysis was restricted to ICC cases 18 years or older and resident in 
the state of Maryland at the time of diagnosis. Cases without available information on 
their county of residence at the time of diagnosis (n=9) were excluded from all county 
level analyses. 
State and county population data as well as racial composition were obtained from the 
2010 census and used as denominator for all incidence rate calculations. In addition, 
annual median household incomes by county were obtained from the Census Bureau’s 
Small Area Income and Population Estimates 
(https://www.census.gov/did/www/saipe/data/index.html) [96]. Other county 
characteristics were obtained from the Maryland Behavioral Risk Factor Surveillance 
System (BRFSS) [97]. For each county, BRFSS data included information on prevalence 
of obesity and current smoking as well as percentage of females screened for cervical 
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cancer within the last 3 years. All BRFSS data were obtained biennially (2004, 2006, 
2008, 2010 and 2012).  
Descriptive Statistics  
Characteristics of cases diagnosed within the study period were described using median 
values and associated interquartile range (IQR) values for continuous variables and 
percentages for categorical variables. Choropleth maps of average annual crude incidence 
of ICC by county were developed in ArcGIS [98] for the entire 10-year.  
Space-Time Cluster Detection Analyses  
Spatial epidemiology presents a formal way to separate signal from noise in examinations 
of trends in incidence across geographic units and over time while accounting for 
relevant factors that might influence any observed variation[51-54]. Tools from the field 
of spatial epidemiology, such as the cluster detection approach, allow for the objective 
identification and visualization of geographic areas of anomalous cancer incidence in 
space and time [55]. Further; areas of significantly high or low cancer incidence 
identified using spatial epidemiology can inform efficient redistribution of cancer 
prevention and control efforts [56,33]. 
The study utilized retrospective space-time cluster detection analyses to identify areas of 
both high and low ICC incidence in Maryland from 2003-2012. The cluster detection 
analyses were conducted in SaTScan (www.satscan.org) using county of residence at the 
time of diagnosis, as the geographic unit of aggregation and the initial space-time cluster 
detection analysis was age adjusted.  Adjustments in the SaTScan cluster detection 
algorithm serves to rule out clusters that would appear solely due to the adjusting 
variables. Subsequent and final cluster detection analysis were further adjusted for 
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prevalence of obesity, current smoking, minority (defined as non-white race and/or 
Hispanic ethnicity), percentage up to date on their cervical cancer screening (measured as 
Pap test within past 3 years) and median household income within each county.  
Given the limited ability of SaTScan to adjust for variables of a continuous nature [99-
101], separate Poisson regression analyses for adjusted ICC incidence were performed 
stratified by year in STATA14 [102] . The fitted or predicted mean of the Poisson 
regression model represents the expected number of cases per county and year adjusted 
for the included regression model covariates.  These Poisson regression expected counts 
were imported back into SaTScan for the adjusted cluster detection analyses to search 
and identify clusters not already explained by the clustering of these adjusting variables. 
All cluster detection analyses were conducted using a circular buffer defined from each 
county centroid location and extending out to only consider clusters (collection of 
contiguous counties), which combined are within 50% of the total statewide population at 
risk. In addition, two-year aggregates of time of ICC incidence were utilized to ensure 
enough statistical power for detecting clusters. Significance of space-time clusters 
observed to have higher than expected number of ICC was evaluated using Monte Carlo 
simulations within SaTScan with significance reported as a p-value ≤0.05 [99,103,104]. 





There were 2,172 women diagnosed with ICC in Maryland between 2003-2012. At 
diagnosis, most of the cases (46.7%) were 40-59 years old, with a smaller proportion of 
women below the age of 30 (4.6%) or 70 years or older (15.8%, Table 2-1). A sizeable 
proportion of cases were born in the US (42.2%), many of whom were born in Maryland 
(44.8%, 411/917). Fifty-eight percent of cases were white and 34.5% were black. At 
diagnosis, most cases had some type of insurance (77.2%), had grade III or IV cancers 
(28.9%) and no metastasis (64.9%, Table 2-1). Most of the cases were either married or 
had domestic partners (37.6%) while the remainder were separated or divorced (13.9%), 
widowed (11.5%) or had never been married (27.2%, Table 2-1). 
The average annual crude incidence rate of ICC in Maryland over the 10-year period 
assessed, was 7.3 per 100,000 and this rate varied across counties (Figure 2-1). Some 
counties including Baltimore City, Kent and Allegany had overall average annual crude 
rates that were double (~12-15 per 100,000) the crude state rate, while other counties 
including Dorchester and Talbot had crude rates as low as 4 per 100,000 for the 10-year 
period assessed (Figure 2-1). Comparing average annual crude rates by county for the 
earlier 5-year study period (2003-2007) to the later 5-year study period (2008-2012), 
incidence remained fairly stable in some counties, including Baltimore City, Somerset 
and Charles counties (Table 2-2). In contrast, several counties including Allegany, 
Frederick and Garrett counties had lower average annual crude rates in the more recent 5-
year study period. There were other counties including Kent, Washington and Prince 
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George’s counties that experienced an increased average annual crude incidence rate in 
the later 5-year period (Table 2-2).  
This geographic variation in rates was further confirmed in the space-time cluster 
detection analysis, which showed significant space-time clusters of higher and lower than 
expected rates of ICC incidence for certain counties in Maryland (Figure 2-2 & 2-3). 
After adjusting for county age distribution, the overall average annual adjusted statewide 
ICC incidence rate was 9.7 per 100,000.  The most likely cluster, in the initial age 
adjusted cluster detection analysis, was a cluster of higher than expected (RR= 1.82; p-
value<0.01) ICC incidence identified in Baltimore City (Table 2-3), which is a large 
metropolitan area [105] that has a high proportion of low income communities (annual 
median household income in Baltimore City for the time period 2003-2006 ranged from 
$29,162-$35,834 [96] compared to a statewide annual median household income range of 
$58,700- $65,250 [106] for the same time period). The cluster in Baltimore City was 
observed for the time period 2003-2006, and had an average annual adjusted incidence 
rate of 17.1 per 100,000 (Table 2-3). Another significant cluster identified, was a cluster 
of lower than expected (RR=0.78; p-value=0.01) ICC incidence rates that emerged in a 
group of fringe metropolitan [105] higher income counties in south-eastern Maryland 
(annual median household income across these counties for the time period 2005-2008, 
ranged from $63,005-$101,867 [96] compared to a statewide annual median household 
income range of $62,850 - $69,550 [106] for the same time period) (Table 2-3, Figure 2-
2). This cluster of low rate had an average annual age and population size adjusted ICC 
incidence rate of 7.9 and was observed for the period 2005-2008.  
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After further adjustments for percent minority, percent screened for cervical cancer in the 
last 3-years, median household income, percent obese, and percent current smoker within 
each county, the overall average annual adjusted state ICC rate was 9.2 per 100,000. In 
this fully adjusted analysis, two significant clusters of low and 3 significant clusters of 
high rates emerged over the time period assessed (p-value ≤0.05) (Figure 2-3). Both 
clusters of low ICC rates occurred in the more recent calendar years of the study and 
were in primarily rural and suburban counties of various sizes. The most likely cluster in 
this analysis was a cluster comprising six counties in eastern Maryland with a 
dramatically lower incidence of ICC than expected (adjusted relative rate (aRR)=0.082, 
p-value<0.01) for the period 2009-2012. Median income for these mostly 
nonmetropolitan counties ranged from $39,630 - $88,406 and had a Pap screening 
prevalence range of 81.6%-95.2% [97]. The other cluster of low rate (aRR= 0.41; p-
value<0.01) was a secondary cluster, which comprised two large fringe metropolitan 
counties west and northwest of Baltimore, for the period 2009-2012. In this time period, 
counties in this cluster, had a median income range of $60,543-$108,234 [96] and a 
screening prevalence range of 86.7%-92.2% [97]. Comparatively for this time period, 
2009-2012, the statewide screening prevalence range was 82.1%- 86.7% [97] and median 
income ranged from $69,193 to $71,122 [106]. 
The first significant cluster of high ICC rate (aRR=2.52; p-value<0.001), identified in the 
fully adjusted analysis, was observed for the period 2005-2008 in Allegany and Garrett 
counties, which are respectively small metropolitan and rural counties in Western 
Maryland. For this cluster, median income ranged from $33,643 to $43,496 and Pap 
screening prevalence ranged from 72.5% to 83.6% within the time period identified. In 
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this time period, 2005-2008, prevalence of screening in Maryland ranged from 84.1% to 
87.6% and median income ranged from $62,850 to $69,550. 
Baltimore City remained a cluster of high rate (aRR=1.74, p-value<0.001) in the fully 
adjusted analysis, however unlike the initial cluster of high rate identified in the age and 
population size adjusted analysis, this cluster was for a more recent time period, 2009-
2012. In Baltimore City, median income within this time period ranged from $38,186 to 
$39,077 and screening prevalence ranged from 82.0% to 84.9%. Another cluster of high 
rates (aRR=2.47, p-value=0.001) emerged in rural western Maryland in Frederick county 
for the period 2011-2012 (Table 2-3, Figure 2-3). For this time period, median income 
within this county ranged from $77,872 to $80,427 and Pap screening prevalence was 
67.1%.  The last cluster of high rate (aRR= 1.33) identified in the adjusted analysis was 
observed in the suburban large fringe metropolitan county of Montgomery; however, this 
cluster was not statistically significant (p-value= 0.24) and was for the period 2003-2006. 
Median income range for this cluster was $76,669-$87,019 and screening prevalence 
range was 85.3%-90.6%. Comparatively statewide screening prevalence range was 




In this retrospective space-time cluster detection analysis of ICC incidence in Maryland, 
most counties had consistently moderate ICC incidence across the time period examined. 
However, several hotspots of high and low incidence were also detected. These findings 
show that although overall statewide ICC incidence is generally low, there are areas, even 
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in the most recent time period that experienced an irregularly high incidence of ICC. 
Clusters of low ICC incidence identified provide evidence of the impact of state and 
county level efforts to address ICC in Maryland and suggest that ongoing prevention and 
control efforts have been highly successful in specific areas of the state. Understanding 
these remaining areas of anomalous ICC incidence can help to help prioritize additional 
interventions or outreach that may be most impactful.  
The ICC clusters identified in Maryland by our study are not explained by the age 
distribution, average screening rates in the county, health status (smoking and obesity), 
median household income and health insurance coverage within counties contained in the 
clusters identified. Of course individual level impact of these factors remains, especially 
as most ICC cases are known to be underscreened or never screened [15,14,13]. Our 
adjustment for average county screening suggests the clusters observed are not due to 
availability of screening in the area, but to other barriers that affect screening in these 
women. In addition, we cannot rule out the potential for residual confounding even for 
the factors adjusted for in our analysis. Further, other factors that we did not have data on 
may contribute to the elevated rates in the clusters of high incidence including possible 
risk factors such as a lower proportion of women who seek follow-up testing after an 
abnormal Pap test result [107], delays in follow-up testing after an abnormal result 
[108,107] as well as a higher proportion of women living with HIV [109,110] within 
counties in the identified clusters of high incidence. Although highly effective treatments 
currently exist for cervical abnormalities, delays in follow-upon abnormal screening 
results, especially among minority groups have been associated with an increased 
cervical cancer incidence [108,107,111].  
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The average annual age adjusted incidence of 9.7 per 100,000 observed in our study for 
Maryland is comparable to the reported national rate of 7.7 per 100,000 within the same 
time period [31]. In addition, within our study period (2003-2012), the national average 
age annual adjusted ICC incidence decreased significantly at a rate of 1.3% [31]. In spite 
of the decrease in national rates and a comparable national and Maryland state average 
annual ICC rate, the findings of our cluster detection analysis support our study 
hypothesis. They indicate that even in recent time periods, the burden of ICC is uneven 
across smaller geographic units and that there are still some counties experiencing an 
anomalously high ICC incidence. Thus, identifying and investigating these units can 
further accelerate the decline of ICC incidence at the national and state levels.   
Our analysis of variation in cervical cancer incidence among counties in Maryland has 
several strengths and to our knowledge this is one of the first studies to assess the space-
time variation of ICC incidence at the county level. Our study included 10 years of data 
to allow for assessments of temporal variation, and incorporated information on county 
characteristics from different data sources to assess if there are significant space-time 
clusters that are not explained by the county characteristics. The detection of significant 
clusters of both high and low ICC incidence provides additional data that can be used to 
prioritize ICC needs at the county level and ensure effective ICC prevention and control.   
This study also has some limitations. Our evaluation of a space-time variation in ICC 
incidence was conducted at the county level and could not explore potential heterogeneity 
in incidence rates that may be present at smaller geographic units, such as census tracts, 
within each county [112,51].  However, given the relatively low number of ICC cases, 
conducting our analysis at the county allowed for an adequate sample size within each 
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geographic unit [51]. A second limitation is that these county based findings and resulting 
inferences made about ICC risk at the county level may not hold true at smaller 
geographic units or for individuals within those counties[51,113].  
In conclusion, the observed clusters of high and low ICC incidence provide evidence of a 
significantly non-uniform ICC incidence across counties in Maryland within the 10-year 
period assessed. The clusters of lower than expected rates identified provide evidence 
supporting the impact of state and local efforts to address ICC. While the clusters of 
higher than expected rates suggest that in spite of the progress made over time, some 
counties have seen an increased ICC incidence rate, which should be monitored and 
considered for targeted interventions. 
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Table 2-1. Characteristics at diagnosis of 2172 invasive cervical cancer cases 18 years or 
older, diagnosed in Maryland between 2003 to 2012 
 
Descriptor n (%) 
  
Age at diagnosis, years  
≤29 99  (4.6) 
30-39 402  (18.5) 
40-49 576  (26.5) 
50-59 439  (20.2) 
60-69 314  (14.5) 




917  (42.2) 
Maryland 411  (18.9) 
DC, VA, PA 144  (6.6) 
North East (other than PA) a 69  (3.2) 
Midwest b 25  (1.2) 
West coast c  7  (0.3) 
South (other than DC, VA, MD) d 98  (4.5) 
Other / U.S. region unknown 163  (7.5) 
Outside United States 150  (6.9) 
Africa 28  (1.3) 
Europe 9  (0.4) 
South America & Caribbean 65  (3.0) 
Asia & Middle East 27  (1.2) 
Other 21  (1.0) 
   Unknown 1105  (50.9) 
  
Race  
Black 750  (34.5) 
White 1254  (57.7) 
Other  143  (6.6) 
Unknown 35  (1.6) 
  
Insurance status  
Uninsured 131  (6.0) 
Private Insurance 748  (34.4) 
Public Insurance 586  (27.0) 
Other 345  (15.9) 
Unknown 362  (16.7) 
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Descriptor n  (%) 
  
Type of reporting source  
Medical provider/Health facility 1976  (91.0) 
Lab only 155  (7.1) 
Death certificate 41  (1.9) 
Unknown 0  (0.0) 
  
Grade  
I 213  (9.8) 
II 537  (24.7) 
III/ IV 627  (28.9) 
Unknown 795  (36.6) 
  
Metastasis  
No 1410  (64.9) 
Yes 201  (9.3) 
Unknown 561  (25.8) 
  
Diagnostic confirmation  
Histology 1952  (89.9) 
Cytology 76  (3.5) 
Clinical 12  (0.6) 
Unknown 132  (6.1) 
  
Marital status  
Never married 591  (27.2) 
Married/Domestic partner 817  (37.6) 
Separated/Divorced 262  (12.1) 
Widowed 216  (9.9) 
Unknown 286  (13.2) 
  
a Northeast: Connecticut Delaware Massachusetts Maine New Hampshire New Jersey New York Rhode 
Island Vermont [47] 
b Midwest: Illinois Indianapolis Kansas Michigan Missouri Nebraska Ohio Wisconsin 
c West coast: California Colorado Hawaii Washington [47] 
d South: Alabama Arkansas Florida Georgia Kentucky Louisiana Mississippi North Carolina South 
Carolina Oklahoma Tennessee Texas West Virginia [47] 
e Others: Guam 
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Table 2-2. Average annual crude incidence of invasive cervical cancer per 100,000, by 
counties in the state of Maryland, for the time periods 2003-2007 and 2008-2012 
 
County 
Average annual crude rate 
per 100, 000 a 
2003-2007 2008-2012 
   
Charles 6.1 4.6 
Somerset 6.3 2.5 
Frederick 6.9 8.6 
Caroline 7.1 7.1 
Garrett 8.0 9.3 
Harford 8.0 7.6 
Anne Arundel 8.3 8.8 
Cecil 8.4 6.2 
Carroll 8.6 8.6 
Montgomery 8.7 10.3 
Talbot 8.8 11.4 
Prince George's 8.9 6.7 
Calvert 9.7 4.8 
Queen Anne's 10.1 8.5 
Baltimore City 10.2 9.2 
Baltimore County 10.4 7.4 
Washington 10.6 9.0 
Kent 10.6 7.3 
Wicomico 11.2 9.4 
Dorchester 11.3 7.8 
Howard 12.0 12.0 
Worcester 15.0 14.0 
St. Mary's 15.4 15.4 
Allegany 15.7 10.7 
   



















      
Age-Adjusted a      
   Most likely cluster: Baltimore City  17.1 1.76 1.82 <0.001 2003-2006 
Secondary Clusters:  











 Caroline, Talbot and Queen Anne’s 1.0 0.11 0.11 0.228 2011-2012 
      
Fully Adjusted b       
Most likely cluster: Dorchester, Talbot, Caroline, Wicomico,  











Secondary Clusters:  











 Carroll and Howard 3.8 0.42 0.41 <0.001 2009-2012 
 Frederick 22.4 2.44 2.47 0.001 2011-2012 
 Allegany and Garrett 22.9 2.50 2.52 0.002 2005-2008 
 Montgomery 11.9 1.30 1.33 0.150 2003-2006 
      
a Average annual statewide ICC incidence for the age-adjusted analysis was 9.7 per 100,000 and the analysis was adjusted for county age distribution. 
b Average annual statewide ICC incidence for the adjusted analysis was 9.2 per 100,000 and the analysis adjusted for age distribution, percent minority, 









Figure 2-2. Age-adjusted map of significant (p≤0.05) space-time clusters of high (red) and low (green) invasive cervical cancer 




Figure 2-3. Adjusted map of significant (p≤0.05) space-time clusters of high and low invasive cervical cancer incidence rates by 
county in Maryland, 2003-2012. Adjusted for age distribution, median household income, cervical cancer screening rates, prevalence 
of smoking and obesity within each county. 
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CHAPTER 3: SCREENING 
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Pap Test Utilization Among Women Living With HIV Enrolled In Primary Care: A 








Previous evaluations of Pap testing among women living with HIV (WLWH) have 
mostly been cross-sectional or had relatively short follow-up Therefore this study was 
conducted to longitudinally describe utilization and determinants of Pap testing among 
WLWH over a 10-year period.  
Methods: 
Data were obtained by linking medical and pathology records of WLWH seen at Johns 
Hopkins Hospital between 2005 and 2014. Determinants were assessed using Prentice, 
Williams, Peterson models.  
Results: 
Of 554 WLWH in care for ≥18 months, a large proportion (79%) received Pap testing, 
however only 11% consistently received Pap testing at the recommended annual interval. 
Some women (5%) were consistently under-screened (tested at intervals longer than 18-
months) and 21% did not receive any Pap testing at during follow-up.  
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WLWH with decreased likelihood of screening included older women (per decade 
aHR=0.94, 95%CI: 0.89, 0.99), injection drug users (aHR=0.80, 95%CI: 0.70, 0.93), 
white women (aHR=0.85, 95%CI: 0.72, 1.00) and those who had lived for a longer time 
with HIV (per decade aHR=0.90, 95%CI: 0.81, 0.99). In contrast, only women with a 
prior abnormal Pap result were more likely to receive Pap testing (aHR= 1.66, 95%CI: 
1.44, 1.92). CD4 cell count and health insurance were not significant determinants.  
Conclusion: 
Although many WLWH in care receive Pap testing, some WLWH remain unscreened or 
underscreened. Significant determinants of Pap testing for WLWH include socio-
demographic factors and a prior abnormal result. These present potential targets in an 
urban HIV care setting for closer monitoring and directed interventions to improve 





In 2012, the Centers for Disease Control estimated about 284, 500 women were living 
with HIV (WLWH) in the United States [114]. Even with tremendous improvements in 
clinical management of HIV, WLWH still represent an important high-risk subgroup for 
cervical cancer with their current incidence of cervical cancer being 4-fold higher than 
that of the general population [24]. Additionally, treatment response and survival rates 
are much lower among WLWH diagnosed with cervical cancer than for women in the 
general population [115,116]. Thus, routine Pap testing is recommended and is important 
for all WLWH.  
Until recently, screening guidelines for WLWH were similar to those for the general 
population, suggesting annual Pap testing, except for women newly diagnosed with HIV 
who were recommended to receive a Pap test twice in the first year post HIV diagnosis 
[117]. More recently, guidelines in the general population have changed to suggest Pap 
testing every three years after a normal Pap [118]. Guidelines for WLWH also changed in 
2015 to suggest a three-year follow-up interval among women with 3 consecutive normal 
Pap test results [66].  However, by virtue of their higher risk, annual Pap testing is still 
recommended for WLWH with one or two consecutive normal Pap tests results [66]. 
in its 2012 report to congress the United States Preventive Services Task Force identified 
the limited evidence base on utilization of cervical cancer screening as one of the barriers 
to effective prevention and control in the US [119]. Indeed, among women diagnosed 
with cervical cancer in the US, most were enrolled and regularly accessing healthcare 
services but were never screened (50%) or underscreened (10%) in the years prior to 
diagnosis [12,14]. Furthermore, despite the recommendation for frequent Pap testing 
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among WLWH, some previous studies suggest that Pap testing remains underutilized, 
even for WLWH enrolled in clinical care [16,61,21,22]. Initial studies exploring barriers 
to Pap testing among WLWH identified older age, blacks and other racial minorities, low 
socioeconomic status, low CD4 cell count and low level of education to be associated 
with the underutilization of Pap test services by WLWH [120,61,16,22].  
In one of the largest studies to date of Pap test utilization among WLWH, a cross-
sectional survey of WLWH across 18 states reported a sizable proportion (23%) did not 
receive Pap testing [61] .  Focused group interviews on utilization of gynecologic 
services by WLWH at the Moore clinic of Johns Hopkins in 2008 suggested 22% of 
women never received a Pap test in the preceding year [21]. Relying solely on electronic 
records, a study of WLWH in care at Boston Medical Center reported an even higher 
proportion (47%) of women did not receive annual Pap testing [16]. However, these 
previous studies were largely been cross-sectional in nature, relied on self-reports, or 
followed WLWH for a relatively short period of time [16,17,21-23]. Thus, to address 
these limitations, the current study evaluated utilization and determinants of cervical Pap 




Study Design and Population   
A longitudinal study of WLWH enrolled in clinical care within a retrospective 10-year 
period, from January 1, 2005 to December 31, 2014, was performed. This study utilized 
data collected as part of the Moore Clinic cohort, which is composed of people living 
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with HIV in Baltimore who are followed up longitudinally through medical record based 
abstraction of demographic, behavioral and clinical data at regular six months intervals 
[121]. Among 669 women in the cohort and in care during this timeframe, the analysis 
was restricted to 554 WLWH who were: at least 18 years old, had basic demographic 
information available in their medical records and had clinical follow-up for at least 18 
months (to allow an opportunity to be screened). For 54 women, who met the inclusion 
criteria and were newly diagnosed with HIV, only data collected on or after HIV 
diagnosis were utilized in this analysis; data prior to diagnosis was excluded.  
Outcome  
The primary outcome of interest for this study, receipt of a Pap test, was defined using a 
binary indicator (yes or no). As this was a recurring outcome, women could experience 
multiple Pap tests during clinical follow-up. After every Pap test, each woman was 
considered to be at risk for her next event (Pap test) until the end of time spent in clinical 
care or until the end of the 10-year period.  
Although all WLWH are recommended to have at least an annual Pap test, we allowed a 
window of 18 months before considering a participant as not having received an annual 
Pap.  This expanded period allowed us to be specific in our definition of underscreening, 
Further, to ensure accuracy of data used in this study, individual medical records were 
linked to the Johns Hopkins Hospital pathology database using unique patient identifiers. 
Determinants of Pap Testing 
Information assessed at entry and treated as fixed variables in the analysis included: 
smoking status (current or never/former), injection drug use (yes or no), race (black, 
white or other), date of HIV diagnosis, and body mass index (BMI) calculated using 
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recorded weight and height (underweight / normal: ≤24.9, overweight: 25-29.9 or 
obese≥30.0). Time-varying variables evaluated at entry and at each screening visit, 
included: type of health insurance (public {Medicare/Medicaid}, private, Ryan White 
health insurance and uninsured/out of pocket payment) and current CD4 cell count. At 
screening visits where information on time varying variables was not available, 
information about those variables from a preceding visit was utilized. Results of the 
preceding Pap test were also assessed at each screening visit and categorized as: normal 
(“negative for intraepithelial lesion or malignancy”), atypical squamous cells of 
undetermined significance (ASC-US) or atypical glandular cells of undetermined 
significance (AGUS), low-grade squamous intraepithelial lesions (LSIL), and high-grade 
squamous intraepithelial lesions (HSIL) or atypical squamous cells- cannot exclude HSIL 
(ASC-H) [122].  
Statistical Analysis  
Participants were described at entry using median values with corresponding interquartile 
range (IQR) estimates for continuous variables and percentages for categorical variables. 
The total number of Pap tests received during follow-up and the median time interval 
between each Pap test were also assessed. A Kruskal–Wallis test was used to compare 
median Pap test intervals by order of Pap test received and by results of the preceding 
Pap test. Linear trends were assessed using a nonparametric test for trend.  
Prentice, Williams, Peterson gap time models (PWP-GT) were used to evaluate the 
determinants of Pap testing and follow-up for each woman was divided into multiple sets 
of time between Pap tests. These PWP-GT models are multiple failure time to event 
models that use a conditional risk set approach of time since each prior event to account 
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for the multiple time periods within the same women at risk for the event [123]. PWP-GT 
are variance corrected models, which adjust the covariance matrix of estimators to 
account for the dependent nature of the outcome [123]. 
The unadjusted hazard ratio (HR) and 95% confidence interval (95% CI) for each factor 
were assessed. For continuous variables, effects were explored as both continuous and 
categorical variables and rescaling in multiples of ten was done on the continuous scale to 
allow for easy interpretation. Factors observed to be significant in unadjusted analysis or 
those identified by previous studies were included in the adjusted analysis. The adjusted 
model from which adjusted hazard ratios (aHR) were obtained included age, race, 
injection drug use, number of years since HIV diagnosis, results of preceding Pap test, 
CD4 cell count and type of health insurance as covariates. Goodness of fit for the 
adjusted model was assessed using Cox-Snell residuals.  
All statistical tests were two sided and with an alpha ≤ 0.05. Data management and 
analysis were carried out in STATA 14 [102]. The institutional review board of Johns 




There were 554 WLWH who contributed 3,177 person-years to the study and were 
followed for a median of 5.7 years (IQR: 3.7-7.9). Forty-two percent of participants were 
in care and entered our analysis in the first year of the 10-year study period, 2005-06, 
with another 25% and 21% of participants entering the study in 2007-8 and 2009-10, 
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respectively (Table 3-1). At entry, participants had a median age of 41 years (IQR: 34-
48), were predominantly black (79%), and many reported a current smoking status (57%) 
(Table 3-1). Median CD4 count at entry was 307 cells/ µl (IQR: 127-510), and median 
HIV viral load at entry was 7712 copies/ml (IQR: 400-53693). 
Utilization of Pap testing 
Although a large proportion of women received Pap testing (79%), a sizeable proportion 
(21%) never received Pap testing during study follow-up (Figure 1a). Among those who 
received at least one Pap test, some received only one or two (31%), while others had 
three (12%), four (10%) and five or more (26%) Pap tests during follow-up (Figure 3-1a).  
As expected, women who were in care longer were more likely to receive Pap testing 
than women with shorter time in care (Figure 3-1b). Median time in care for women who 
received at least one Pap test during follow-up was 5.1 years (IQR: 3-6.9) compared to 
3.8 years (IQR: 2.3-5.7) among women who never received a Pap test during clinical 
follow-up at Johns Hopkins Hospital. The total number of Pap tests received increased 
linearly with a longer median time in care (Figure 3-1b; np trend <0.001).   
The overall median interval between successive Pap tests during follow-up was 11.3 
months (IQR: 6.2-17.2).  However, median time from entry to the first Pap was longer 
(17.9 months; IQR: 12.0-32.6, Figure 3-2) than the recommended annual interval, and 
women who had only one Pap had a longer median time from entry to Pap than women 
who had 2 or more Pap tests (19.6 vs 7.6 months). After the first Pap, median interval 
remained fairly consistent between subsequent Pap tests and with guideline 
recommendations (Figure 3-2).  
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Using a more stringent definition of screening of twelve months, only 11% of women 
consistently received Pap test according to guideline recommendations. This was 19% of 
women who received two or more Paps during follow-up, highlighting the potential for 
underscreening. Also of note, 5% of women screened consistently received Pap test at 
intervals longer than 18 months.  
Results of 60% of the 1,410 Pap tests conducted during follow-up were reported as 
normal. Abnormal Pap results included ASC-US/AGUS (13% of all Paps), LSIL (13%), 
and HSIL/ASC-H (7%). Nine (<1%) of the Pap tests received did not have documented 
results.  
Median interval between consecutive Pap tests varied significantly (p<0.001) by results 
of the preceding Pap test. For women with a normal result in the preceding Pap test, 
median interval to the subsequent Pap was 14.3 months (IQR: 10.7-20.5) (Figure 3-3). 
However, for women with an abnormal Pap result, this interval was shorter. Specifically, 
median interval for women with a preceding Pap test result of ASC-US/AGUS, LSIL or 
HSIL/ASC-H was 12.0 (IQR: 8.0-20.1), 11.1 (IQR: 7.2-16.5) and 11.0 (IQR: 8.7-16.5) 
months respectively. For women with an unknown Pap test result this interval was 13.8 
months (IQR: 10.8-18.2).  
Determinants of Pap testing  
Several determinants of Pap test utilization were identified (Table 3-2). In unadjusted 
analysis older age (per decade, HR=0.90, 95%CI: 0.85, 0.95), white women (HR=0.84, 
95%CI: 0.72, 0.99), injection drug users (HR= 0.79, 95%CI: 0.68, 0.91), women 
diagnosed with HIV for a longer time (per decade, HR=0.93, 95%CI: 0.79, 0.96) and 
those with an elevated CD4 cell count (per 100 cells/ μL, HR=0.98, 95%CI: 0.96, 1.00) 
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were all significantly less likely to receive a Pap test, each p <0.05. In contrast, women 
with Ryan White health insurance coverage compared to women with Medicaid/Medicare 
(HR=1.27, 95%CI: 1.06, 1.52) and those with a previous abnormal Pap test result 
(compared to a normal result) of either ASC-US/AGUS (HR= 1.47, 95%CI: 1.22, 1.76), 
LSIL (HR=1.75, 95%CI: 1.45, 2.10) or HSIL/ASC-H (HR=2.22, 95%CI: 1.55, 3.17) 
were more likely to receive a Pap test. Former smokers and those who had never smoked 
were also more likely to receive a Pap test than current smokers (HR=1.14, 95%CI: 1.00, 
1.30).  
In the adjusted analysis, women of older age (aHR=0.93, 95%CI: 0.89, 0.98), white 
women (aHR=0.85, 95%CI: 0.72, 1.00), injection drug users (aHR=0.80, 95%CI: 0.70, 
0.93) and women who had lived with HIV for a longer time (aHR=0.90, 95%CI: 0.81, 
0.99) remained significantly less likely to receive a Pap test. By contrast, women with a 
previous abnormal Pap test result of ASC-US/AGUS (aHR=1.40, 95%CI: 1.14, 1.72), 
LSIL (aHR=1.76, 95%CI: 1.45, 2.13) or HSIL/ASC-H (aHR=1.93, 95%CI: 1.40, 2.66) 
remained significantly more likely to receive a Pap test. After adjusting for other 
variables, CD4 cell count and insurance were not significantly associated with Pap testing 
(Table 3-2).  
 
DISCUSSION 
In our longitudinal assessment of Pap testing among WLWH enrolled in clinical care, we 
observed that 21% of WLWH did not receive any Pap testing during follow-up.  
Additionally, only 11% of women consistently received a Pap test at the recommended 
annual interval and 5% were consistently underscreened. The likelihood of receiving a 
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Pap test for WLWH enrolled in clinical care, was associated with some of the socio-
demographic, clinical and behavioral factors examined. Older women, white women, 
intravenous drug users and women who had lived with HIV for a longer time were less 
likely to receive a Pap test. These findings contribute to the existing evidence base on Pap 
test utilization among WLWH enrolled in clinical care. They suggest groups that may 
need to be closely monitored to ensure receipt of Pap testing as recommended.  
The associations observed between older age, injection drug use and a decreased 
likelihood of receiving a Pap test are consistent with the findings of previous studies that 
also reported that these biologic and behavioral risk factors can affect screening 
frequency [16,124,21]. Even though Pap testing is recommended throughout a WLWH’s 
life [66] older women are often perceived to have a lower risk of cervical cancer, which 
makes them less likely to receive Pap testing. Compared to non-users, injection drug 
users living with HIV have been noted to only partially engage in care [125] and as such 
may not have the opportunity to receive all required medical services. This might explain 
the decreased association observed for injection drug users. Although several previous 
studies have reported white WLWH are more likely to receive Pap testing compared to 
black WLWH, we observed a marginally lower likelihood of screening among white 
WLWH. This finding is consistent with a previous study conducted in an urban health 
facility, which reported a twofold increased odds of non-adherence among white WLWH 
compared to black WLWH [16]. This may in part reflect differential healthcare access 




Our finding of a decreased likelihood of Pap testing among women with a longer time 
since HIV diagnosis, independent of older age, has not been previously reported. This 
decrease is potentially a result of the greater number of competing health priorities that 
develop as people live longer with HIV, which decreases their likelihood of receiving Pap 
testing. Similar to what we found, some studies have identified a prior abnormal Pap 
result as a predictor of future screening in both the general population [128] and WLWH 
[16,129]. In this study, we could not discern whether the increased screening was driven 
by provider or patient motivations for screening. 
The proportion of unscreened women in our study is higher than that reported for the 
general US population [130] and falls well above the healthy people 2020 target of 7% 
[131].  However, the proportion of unscreened women observed in our study is consistent 
with previous studies. These previous studies have reported 19-25% of WLWH in the 
United States do not receive Pap testing [23,61,16,22]. In addition, our findings suggest 
that even when women are in care over several years in the same clinic some WLWH 
remain underscreened or unscreened. This study could not however, evaluate whether 
women were refusing screening when offered.  
Pap test intervals for WLWH have not been widely assessed and reported. To our 
knowledge this is one of the few evaluations of time intervals between Pap test for 
WLWH. Although the overall median interval between Pap test was fairly consistent with 
prevailing guideline recommendation [132], the proportion of women consistently 
screened throughout clinical follow-up, at or around the recommended annual interval, 
was low. Some women were consistently underscreened and intervals varied widely for 
the first few Paps. This suggests that although a sizeable proportion of WLWH receive 
 
 51 
Pap testing regularly while in care, there are other WLWH who are infrequently screened 
and have much longer Pap tests intervals than guideline recommendations.  
This study has several strengths including our use of a comprehensive longitudinal 
history of Pap testing, confirmed by pathology data. Unlike previous studies, the longer 
period evaluated in this study allowed description of screening patterns and time between 
Pap tests to be assessed. Our study may not have captured Pap test received outside of 
Johns Hopkins Hospital, so we cannot exclude the possibility that some women were 
screened elsewhere and therefore the prevalence of underscreening would be 
overestimated in this study. To minimize the potential for this to occur, our analysis was 
restricted to participants who were enrolled in primary care for at least 18 months. In 
addition, most (~85%) of the cohort participants in this study are known to access all of 
their healthcare needs through the Johns Hopkins network [121]. We could not evaluate 
variables not routinely captured in medical records on factors such as patient 
understanding of the importance of Pap testing or personal or access barriers to screening.   
Our findings provide additional evidence that although most WLWH receive Pap testing, 
some women in clinical care are not screened and some women receive Pap testing at 
intervals longer than recommended. Characteristics of WLWH least likely to receive Pap 
testing include older women, women with a longer time since HIV diagnosis, injection 
drug users and white women, which present potential targets in an urban HIV care setting 
for closer monitoring and directed interventions to improve Pap screening in WLWH. 
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Table 3-1. Characteristics of 554 WLWH at their first clinic visit within the study period 
(2005-2014)  
Characteristic n  (%) 
  
Age (years): Median (IQR) 41  (34-48) 
<30 79  (14.3%) 
30-39 162  (29.2%) 
40-49 201  (36.3%) 
≥50 112  (20.2%) 
  
Race  
Black 440  (79.4%) 
White 92  (16.6%) 
Other 22  (4.0%) 
  
Baseline CD4 cell count (cells/μL): Median (IQR) 307  (127-510) 
<200 180  (32.5%) 
200-499 229  (41.3%) 
≥500 144  (26.0%) 
Unknown 1  (0.2%) 
  
Baseline HIV viral load (copies/mL): Median (IQR) 7712  (400-53693) 
Unknown 5  (0.9%) 
  
Time since HIV diagnosis (years): Median (IQR) 2.1  (0.1-8.9) 
0-4 326  (58.8%) 
5-14 158  (28.5%) 
≥15 63  (11.4%) 
Unknown 7  (1.3%) 
  
BMI (kg/m3): Median (IQR) 27.43  (23.6-33.1) 
Underweight: <18.5 15  (2.7%) 
Normal: 18.5-24.9 119  (21.6%) 
Overweight: 25-29.9 118  (21.5%) 
Obese: ≥30.0 149  (27.1%) 
Unknown 149  (27.1%) 
  
Smoking status  
Current 315  (56.9%) 
Former 33  (6.0%) 




Characteristic n  (%) 
  
Injection drug use  
Yes 146  (26.4%) 
No 408  (73.7%) 
  
Calendar years of study entry  
2005-2006 234  (42.2%) 
2007-2008 142  (25.6%) 
2009-2010 118  (21.3%) 
2011-2015 60  (10.8%) 
  
Type of health insurance  
Public (Medicaid/Medicare) 89  (16.1%) 
Private 42  (7.6%) 
Ryan White 49  (8.8%) 
Uninsured/Out of pocket 6  (1.1%) 
Unknown 368  (66.4%) 
  
Total amount of follow-up in clinical care (years): Median 
(IQR)  




Table 3-2. Factors associated with utilization of Pap Testing by WLWH enrolled in care 


















       
Age, per 10 years 0.90 (0.85 - 0.95) <0.01 0.93 (0.89 - 0.98) 0.01 
<30 (ref) 1.00 -- -- 1.00 -- -- 
30-39 0.97 (0.80 - 1.16) 0.72 1.01 (0.84 - 1.21) 0.94 
40-49 0.93 (0.78 - 1.11) 0.43 0.98 (0.82 - 1.16) 0.79 
≥50 0.72 (0.59 - 0.88) <0.01 0.81 (0.67 - 0.99) 0.04 
p for trend  <0.01   0.02   
       
Race       
Black (ref) 1.00 -- -- 1.00 -- -- 
White 0.84 (0.72 - 0.99) 0.03 0.85 (0.72 - 1.00) 0.04 
Other  0.87 (0.60 - 1.24) 0.44 0.77 (0.53 - 1.11) 0.16 
       
Injection drug use 0.79 (0.68 - 0.91) <0.01 0.80 (0.70 - 0.93) <0.01 
Time since HIV 
diagnosis, per 10 
years 
0.93 (0.89 - 0.98) <0.01 0.90 (0.81 - 0.99) 0.03 
0-4 (ref) 1.0 -- -- 1.00 -- -- 
5-14 0.78 (0.69 - 0.89) <0.01 0.84 (0.74 - 0.95) 0.01 
≥15 0.84 (0.72 - 0.99) 0.04 0.88 (0.74 - 1.05) 0.17 
p for trend 0.15   0.08   
       
Results of 
preceding Pap test   
      
Normal (ref) 1.0 -- -- 1.00 -- -- 
Any abnormal  1.66 (1.45 -1.90) <0.01 1.66 (1.44 - 1.92) <0.01 
ASC-US 
or AGUS 
1.47 (1.22 - 1.76) <0.01 1.40 (1.14 - 1.72) <0.01 
LSIL 1.75 (1.45 - 2.10) <0.01 1.76 (1.45 - 2.13) <0.01 
HSIL or 
ASC-H 
2.22 (1.55 - 3.17) <0.01 1.93 (1.40 - 2.66) <0.01 
Never received 




(0.91 - 1.53) 
0.22 
 






















       
CD4 cell count, 
cells/100μL 
0.98 (0.96 - 1.00) 0.04 0.99 (0.97 - 1.01) 0.29 
≥500 (ref) 1.0 -- -- 1.00 -- -- 
200-499   1.09 (0.94 - 1.27) 0.25 0.97 (0.85 - 1.09) 0.59 
<200  1.09 (0.94 - 1.26) 0.26 1.00 (0.86 - 1.16) 0.98 
p for trend 0.27   0.90   
       
Type of health 
insurance 
      
Public (ref) 1.0 -- -- -- -- -- 
Private  1.11 (0.94 - 1.32) 0.23 1.04 (0.87 - 1.25) 0.67 
Ryan White  1.27 (1.06 - 1.52) 0.01 1.16 (0.96 - 1.40) 0.13 
Uninsured/Out 
of Pocket  
1.32 (0.85 - 2.06) 0.22 1.20 (0.77 - 1.87) 0.43 
Unknown 0.94 (0.82 - 1.07) 0.34 0.87 (0.76 - 0.99) 0.04 
       
BMI, kg/per 100 
m3 




1.0 -- -- -- -- -- 
Overweight: 
25-29.9 
1.03 (0.87 - 1.23) 0.70 -- -- -- 
Obese: ≥30.0 1.09 (0.93 - 1.28) 0.30 -- -- -- 
Unknown 0.98 (0.84 - 1.16) 0.85 -- -- -- 
p for trend 0.76        
       
Smoking status       
Current (ref) 1.0 -- -- -- -- -- 
Never / Former 1.14 (1.00 -1.30) 0.052 -- -- -- 
Unknown  1.31 (1.11 - 1.55) <0.01 -- -- -- 




Figure 3-1a. Percent of women receiving 0, 1, 2, 3, 4, and 5 or more Pap tests during their follow-up 3-1b. Total time in care (number 




Figure 3-2. Among women screened, time interval (number of years) between current Pap and previous Pap test, by Pap test order. In 
this graph, category 1 represents the 1st Pap within the study, which is time from entry until first Pap. Category 2 represents the time to 
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the 2nd Pap (from the first Pap), among women who had at least 2 Paps, etc. Median and interquartile range is shown. Dotted line 




Figure 3-3. Among women screened, time interval (number of years) between previous and current Pap test, by the preceding Pap test 
results. . In this graph, category 1 represents the time interval from a normal Pap test result until the next Pap test. 
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Category 2 represents the time to the next Pap test, among women with an abnormal Pap 
test result of ASC-US/AGUS, etc. Median and interquartile range is shown. Dotted line 
represents recommended screening interval of 12 months 
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CHAPTER 4: ORAL HPV INFECTION 
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Prospective Study Of Oral HPV Infections Among Women With And Without 








HPV is linked to both cervical and some oropharyngeal cancers. However, there have 
been no prospective examinations of the determinants and risk posed by prevalent 
cervical HPV infections on the incidence of oral HPV infections of the same DNA type. 
Further, current evidence on the correlation between HPV infections at the two anatomic 
sites is limited and inconsistent 
Methods 
Data on 213 women enrolled in the Women’s Interagency Health Study cohort who had 
available data on both oral and cervical HPV infection was utilized. Determinants and 
risk of incident type-specific oral HPV infections were evaluated using Wei-Lin- 
Weissfeld models. Multivariate models included cervical HPV infection status, age, 




Factors associated with an increased risk of incident oral HPV infection included recent 
history of sexual activity with either a male (adjusted hazard (aHR)=2.47, 95%CI: 1.02-
6.01) or female partner (aHR=2.79, 95%CI: 1.14, 6.79) as well as performing oral sex in 
the prior 6 months (aHR=1.75, 95%CI: 1.16, 2.62). A marginal association was observed 
for HIV 1.83 (0.94, 3.56) and no association was observed with cervical HPV infection, 
age, alcohol or condom use during oral sex.  
Conclusion 
Having a prevalent cervical HPV infection was not associated with an increased risk of 
acquisition of oral HPV infection; however, sexual activity remains a significant risk 






Human Papillomavirus (HPV) infections cause cervical cancer, anal cancer, as well as 
many oropharyngeal cancers. In the United States, 40-80% of oropharyngeal cancers and 
over 90% of invasive cervical cancers are associated with HPV [70-72]. However, in 
spite of this association, currently the relationship between HPV infections at these two 
independent anatomic sites is not well understood [25]. Further there are unanswered 
questions about the potential risk and determinants associated with transfer of prevalent 
infections between the two anatomic sites.  
Even though HPV infections are transmitted primarily through sexual contact, it may be 
possible to transmit infections through non-penetrative sexual contact through means 
such as either masturbation or autoinoculation [67,68]. Autoinoculation refers to the 
“transmission of a prevalent HPV infection between the genitals, anal canal, oral cavity 
or hands of an infected individual during routine genital self-handling” [67,69]. 
Plausibility for autoinoculation of HPV infections is supported by evidence from a cohort 
of newly sexually active females where HPV DNA was detected in the fingertips of 30% 
of women with prevalent cervical infections of at least one HPV type [68]. In this study, 
the concordance rate between types detected in cervical and fingertip samples was 60% 
and over 90% of these had the same variants detected in both cervical and fingertip 
samples [68]. Suggesting that outside of the sexual mode of transmission, transfer of 
infections between anatomic sites such as the cervix and oropharynx may occur through 
deposition of infections on the fingertips of individuals with prevalent HPV infections.  
Further a cross-sectional examination of the correlation between prevalent oral and 
cervical HPV infections, comparing women with and without cervical HPV infection, 
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observed that the prevalence of oral HPV infections among women with cervical HPV 
infections was significantly higher than among women without any cervical HPV 
infection (25.5% versus 7.9% p-value= 0.002) [75]. A more recent study using national 
survey data in the United States, observed a 5-fold increased prevalence of oral HPV 
infections among women with cervical infections compared to women without any 
cervical HPV infection [76]. Using data from 10 studies a meta-analysis of the correlation 
by type between cervical and oral HPV infections reported a pooled prevalence of 18.1% 
for oral HPV infections among women with a cervical infection [77].  
Although these previous studies suggest an increased risk for oral HPV infection among 
women with a cervical infection, due to their mainly cross-sectional nature [78,75,79] the 
temporal sequence and risk of oral acquisition of HPV from prevalent cervical infections 
is presently unknown. Further these previous studies have been severely limited by their 
sample size and overall the available evidence base on the correlation between cervical 
and oral HPV infection is inconsistent. Therefore, this study sought to prospectively 
evaluate the co-factors and risk conferred by prevalent type-specific cervical HPV 
infections on the subsequent acquisition of the same HPV types orally. 
 
METHODS 
Study Design and Population 
Data from the Persistent Oral Human Papillomavirus Study (POPS) was utilized for this 
study. POPS is a prospective cohort study of oral HPV infection nested within the larger 
Multicenter AIDS Cohort Study (MACS) and Women’s Interagency Health Study 
(WIHS), which are respectively multicenter cohort studies of HIV infection in men and 
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women. Recruitment into POPS was carried out from October 2009 to October 2011 
across multiple sites, using a convenience sample of HIV infected and high-risk HIV 
negative participants.  
Participants in this analysis included a sample of women (N=213) enrolled in POPS 
between October 2009 and October 2014 at 3 study sites specifically Brooklyn, Bronx 
and Chicago. These 213 women represented 22.3% of all women in POPS. Other female 
participants were excluded because they did not have available cervical HPV testing 
results, within the time period examined. Participants were only included if they had at 
least one assessment of cervical HPV infection status, either on or after October 2009. In 
addition, all participants were required to have at least 2 available assessments of their 
oral HPV infections status, one at entry and the other during follow-up. Entry for this 
analysis was defined as the first POPS visit where cervical HPV infection status was 
assessed and after entry participants were followed up regularly at approximately 6-
months intervals until the end of follow-up or censoring.   
Specimen Collection  
Female participants enrolled in POPS are all part of the WIHS cohort where they provide 
cervical swabs and cervicovaginal lavage samples at each semiannual visit. Many (but 
not all) of these cervical samples have been tested for cervical HPV, allowing comparison 
of cervical HPV and oral HPV (assessed) at these study visits. In addition, at each visit 
participants fill out an interviewer-administered questionnaire, which is used to collect 
risk factor information on recent behaviors and exposures including sexual practices, 
alcohol use, smoking, number of sexual partners and sexual orientation. 
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Assessment of Cervical HPV Infection  
The main exposure of interest in this study was type-specific cervical HPV infection and 
to assess this, cervicovaginal lavage fluid and cervical swab samples provided at entry 
were tested for the presence of HPV DNA [133]. The HPV types tested for in collected 
cervical samples, included both oncogenic and non-oncogenic HPV types. Specifically, 
oncogenic HPV types assessed included: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 
and 73 [134,135,133]. The non-oncogenic HPV types assessed included: 6, 11, 26, 42, 
53, 54, 61, 62, 64, 66, 67, 69, 70, 71, 72, 81, 82, 83, 84 and 89 [134,135,133].  
Assessment of Oral HPV Infection  
The primary outcome of interest in this analysis was incidence of type-specific oral HPV 
infections observed during follow-up. This outcome was assessed using oral rinse 
samples containing exfoliated epithelial cells provided by each participant after a 30 
second gargle, first at the entry visit and at each subsequent six-months follow-up visit 
[134]. These oral rinse samples were assayed for the presence of HPV DNA associated 
with the same type-specific HPV infections evaluated and described above under 
exposure assessment for cervical HPV infection.  
For both cervical and oral rinse samples, the HPV DNA types of interest were tested for 
using amplification with PGMY09/11 polymerase chain reaction primer pools and 
primers for βglobin [134]. This was then followed by reverse line blot hybridization to 
the Roche LINEAR ARRAY HPV Genotyping Test (Roche Molecular Systems, 




Characteristics of participants in our study were described using median values with 
associated interquartile range estimates for continuous measures and percentages for 
categorical variables.  A Kaplan Meier plot was used to assess time to incident type-
specific oral HPV infection by cervical HPV infection status at entry. Comparing women 
with and without type-specific infections, the risk and determinants of type-specific oral 
HPV infections were explored using Wei-Lin-Weissfeld models. The adjusted model 
included both factors found to be significant in the unadjusted model as well as factors 
previously identified to be associated with oral HPV infections. Specifically, the adjusted 
model included age in years on a continuous scale and HIV status defined using a binary, 
yes or no. In addition, the adjusted model included reported sexual history (no sex, sex 
with female partner or sex with male partner only), performance of oral sex (yes or no) 
and condom use during oral sex (yes or no) within the 6 months period prior to each 
study visit during follow-up. Both the adjusted and unadjusted associations were explored 
at a significance level of p ≤ 0.05. All statistical analyses were conducted using STATA 
14 [102].  
 
RESULTS 
Characteristics of Study Sample 
There were 213 women enrolled at the Brooklyn, Bronx and Chicago sites of the POPS 
and WHIS cohort who had available cervical and oral type-specific HPV data. Median 
age of participants was 47.5 years (IQR: 41.4-53.2, see Table 4-1) and about 73% of 
participants were HIV positive.  Most (79.3%, see Table 4-1) women were heterosexual 
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and almost all participants (94.4%) had a history of ever being pregnant. At entry to this 
substudy (i.e. first study visit in October 2009 or thereafter), 73.0% of women reported 
recent sexual activity within the prior 6 months and this was primarily (68.3%) with a 
male partner. In addition, 4.7% (Table 4-1) of women reported recent sex with a female 
partner with 27% reporting no recent sexual activity.  The percentage of women who 
received oral sex or performed oral sex in the prior 6 months were 30.5% and 28.2% 
respectively (Table 4-1). Participants were predominantly non-Hispanic Black (66.7%) 
and most (65.3%) reported an annual income below the federal poverty threshold of 
$12,060 [136]. Overall, less than half of participants reported alcohol use and this 
included 16.9% of women who had more than 7 drinks each week (Table 4-1).  
Prevalence of exposure and incidence of outcome 
Proportion of women with one or more type-specific cervical HPV infections at entry 
was 12.2% (26). Of the 67 type-specific cervical HPV infections identified at entry, HPV 
62 was the most common cervical HPV infection type with a prevalence of 11.9%. Other 
HPV types common in cervical samples at entry included HPV 53 and 83, which each 
had a prevalence of 9.0%. Only 9 of the type-specific cervical HPV infections detected at 
entry correlated by type with HPV infections detected in oral rinse samples for the same 
individuals at entry and these included infections with HPV types 18, 39, 53, 56, 59, 62 
and 83.  
In the sample of women enrolled in this study, oral HPV prevalence was higher at study 
entry than cervical HPV prevalence. About 40% (85/213) of participants had one or more 
type-specific oral HPV infections, including 152 type-specific oral HPV infections. The 
most prevalent oral HPV type identified at entry was HPV 16, which was detected in 
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9.4% (20/213) of women. The second and third most common oral HPV types detected at 
entry were HPV 62 and 53, which each had a prevalence of 6.1% (n=13) and 4.7% 
(n=10) respectively.  
A total of 969 incident type-specific oral HPV infections were identified and the overall 
incidence rate of type-specific oral infections during follow-up was 6 per 1000 person-
year of follow-up. Further, compared to women without cervical HPV infection, women 
who had any type-specific cervical HPV infection experienced a higher incidence rate of 
type-specific oral HPV infections (8.9 vs 9.9 per 1000 person-year of follow-up, Figure 
4-1).  
Risk factors for incident oral HPV infection 
In the unadjusted analysis only HIV infection was significantly associated with the risk of 
an incident oral HPV infection. All of the other risk factors examined including having a 
prevalent cervical HPV infection at entry had no significant association in the unadjusted 
analysis (Table 4-2). 
In the adjusted model a recent history of sexual activity and performing oral sex in the 
prior 6 months were found to be significant. An increased risk of oral HPV infection was 
observed for women reporting a recent history of sexual activity with either a male 
(adjusted hazard (aHR)=2.47, 95%CI: 1.02, 6.01) or female partner (aHR=2.79, 95%CI: 
1.14, 6.79). In addition, performing oral sex in the prior 6 months was associated with an 
increased risk (aHR=1.75, 95%CI: 1.16, 2.62). A marginal association was observed for 
HIV infection (aHR=1.83, 95%CI: 0.94, 3.56) and no association was observed with 





In our assessment of the determinants and risk posed by type-specific cervical HPV 
infections on the acquisition of incident oral HPV infections of the same type, we 
observed no significant difference in the risk of oral infections between women with and 
without one or more type-specific cervical HPV infections at entry. Sexual behavior was 
a significant predictor of an increased risk of acquiring oral HPV infection, including 
performing oral sex and a recent history of having sex with either a male or female 
partner within a recent six months period. As has been reported for males, even among 
HIV positive and high-risk HIV negative women sexual exposure remains an important 
route for the transmission of oral HPV infections. The observed association between an 
increased risk of oral HPV infections and performing oral sex as well as recent sexual 
activity is consistent with what is currently known about the role of sexual exposures in 
the etiology of oral HPV infections [137-139]. 
Data from previous examinations of the contributions of cervical infections to the natural 
history of oral HPV infections have been inconsistent with some studies reporting either a 
null association or an increased risk for oral HPV infection among women with a cervical 
HPV infection. The findings of our study, which is the first prospective examination of 
the role of prevalent cervical HPV infections in the etiology of oral HPV infections, are 
consistent with some previous studies that observed no association [140-142]. This 
absence of an association implies that HPV infections at the two anatomic sites are 
independent and prevalent cervical infections may play no role in the etiology of oral 
HPV infections. On the other hand, this lack of an association may also be as a result of 
the limited number of women who had a prevalent cervical HPV infection at entry.  
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Similarly, no significant difference in the risk of oral HPV infection was observed for 
women who used condoms during oral sex and those who did not. Condoms provide a 
physical barrier, which may protect against HPV infection. However in order to prevent 
transmission of infections, they have to be consistently and correctly used each time oral 
sex is performed [143,144]. Therefore, infrequent or inaccurate use may not necessarily 
protect against infection.   
HIV positive individuals compared to HIV negative individuals have been reported to 
have a 2-3 fold increased risk for acquiring HPV infections [145]. Our study also showed 
a higher incidence of oral HPV infection among HIV-infected subjects, although the 
difference was only marginally significant and this is likely due to the limited sample size 
used. This might also be explained the high prevalence of HAART use among HIV 
positive participants in this study (Supplemental Table1). HAART use has been shown to 
mitigate the risk of oral HPV infection among HIV positive individuals [145].  
The main strength of our study is its use of a prospective cohort design, which allowed 
for the temporal sequence of cervical and oral HPV infections to be accurately 
established. To our knowledge it is the first prospective examination of the role of 
prevalent cervical infections in the etiology of oral HPV infections. Despite these 
strengths, our study is limited by the rarity of the main exposure of interest, cervical HPV 
infection. Only 10% our study sample had one or more cervical HPV infections at entry. 
Therefore, this may have restricted our ability to detect a difference in the rate of oral 
HPV infections between women with and without type-specific cervical HPV infections 
at entry. In addition, the non-random sampling of participants utilized in our study may 
have resulted in the selection of participants who were not representative or less likely to 
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have experienced the exposure (given the lower than expected cervical HPV prevalence 
in this group). Middle-aged women, independent of sexual behavior, are known to have a 
generally low prevalence of cervical HPV infections [146,147] which could also  explain 
the generally low prevalence of the cervical HPV  in our study population.  
To conclude data from our prospective cohort study shows that prevalent cervical HPV 
infections do not increase the risk of incident type-specific oral HPV infections and that 
HPV infections at these two anatomic sites are independent events. In our study, recent 
sex with either male or female partners as well as performing oral sex were the only 
factors associated with an increased risk of oral HPV infections. This provides further 
evidence that minimizing sexual exposure to HPV may be an effective means of reducing 
incidence of oral HPV infections.
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Table 4-1. Characteristics of 213 Participants at Entry  
 
Characteristic Overall (N=213) 
 n  (%) 
  
Age, years: median (IQR) 47.5  (41.4 - 53.2) 
  
Race  
Black non-Hispanic 142  (66.7) 
White non-Hispanic 9  (4.2) 
Hispanic, any race 57  (26.8) 
Other 5  (2.4) 
  
Center  
Bronx 125  (58.7) 
Brooklyn 39  (18.3) 
Chicago 49  (23.0) 
  
Sexual Orientation  
Heterosexual 169  (79.3) 
Lesbian/Bisexual 42  (19.7) 
Unknown 2  (0.9) 
  
Marital Status  
Never Married 47  (22.1) 
Married/Living with partner 53  (24.9) 
Widowed/Divorced/Separated 51  (23.9) 
Other 60  (28.2) 
Unknown 2  (0.9) 
  
Ever pregnant 201  (94.4) 
  
Parity 2  (1-4) 
  
Recent sex history  
No sex 57       (27.0) 
Sex with female partner 10     (4.7) 
Sex with male partner only 144  (68.3) 
  
Received oral sex in the last 6 
months 






 n  (%) 
  
Performed oral sex on either a 
male or female partner in the 
last 6 months 
60  (28.2) 
  
Condom use during oral sex  
Never 45  (21.1) 
Always/ Sometimes 15  (7.0) 
Not sure/Unknown 153  (71.8) 
  
Income  
≤$6000 44  (20.7) 
$6001-$12000 95  (44.6) 
>$12000 72  (33.8) 
Unknown 2  (0.9) 
  
Alcohol  
Abstainer 116   (54.5) 
>0-7 drinks/week 59  (27.7) 
>7 drinks/week 36  (16.9) 
Unknown 2  (0.9) 
  
Smoking status  
Ever 177  (83.2) 
Never 34  (16.0) 
Unknown 2  (0.9) 
  
Level of education  
≤Grade 11 98  (46.0) 
High school 62  (29.1) 
≥College level 50  (23.5) 
Unknown 3  (1.4) 
  




Table 4-2. Factors associated with incidence of type specific oral HPV infections  
 
Characteristic 
Hazard Ratio  
(95%CI) 
Adjusted Hazard Ratio 
(95%CI) 
   
Any type-specific cervical HPV infection 1.10  (0.74, 1.64) 0.99  (0.67, 1.45) 
   
Age at visit 1.00  (0.98, 1.02) 0.91  (0.70, 1.17) 
   
Recent sex history    
No sex Ref Ref 
Sex with female partner 1.54  (0.82, 2.88) 2.79  (1.14, 6.79) 
Sex with male partner only 0.88  (0.62, 1.26) 2.47  (1.02, 6.01) 
   
Performed oral sex 1.12  (0.94, 1.33) 1.75  (1.16, 2.62) 
   
Condom use during oral sex  1.10  (0.92, 1.31) 1.24  (0.94, 1.64) 
   
Alcohol use   
Abstainer Ref Ref 
>0-7 drinks/week 0.75  (0.54, 1.04) 0.89  (0.61, 1.30) 
>7 drinks/week 0.83  (0.53, 1.31) 0.85  (0.48, 1.52) 
   
HIV positive 1.97  (1.14, 3.40) 1.83  (0.94, 3.56) 






Figure 4-1. Kaplan-Meier survival curve of time to type specific oral HPV infection by HIV status, comparing women with and 
without cervical HPV infections at entry 
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CHAPTER 5: SUMMARY OF FINDINGS, IMPLICATIONS FOR 
PREVENTION AND CONTROL OF INVASIVE CERVICAL 
CANCER AND FUTURE DIRECTIONS
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Utilizing various data sources this research evaluated the prevention and control of ICC 
among high-risk women within the United States.  Specifically, this research assessed the 
space-time variation in ICC incidence by counties in the state of Maryland. This research 
also longitudinally assessed trends and determinants of cervical Pap testing among 
WLWH enrolled in primary care and finally this research evaluated the determinants and 
risk posed by prevalent type-specific cervical HPV infections on the acquisition of the 
same HPV types orally. The overarching oral of this thesis research was to generate 
scientific evidence to facilitate a more targeted approach to addressing the specific needs 
of the subgroups at highest risk for ICC.  
SUMMARY OF MAJOR RESEARCH FINDINGS 
In chapter 2 results of our examination of the space-time variation in ICC incidence by 
counties in the state of Maryland showed most counties had consistently moderate ICC 
incidence across the 10-year period examined. The average annual age adjusted incidence 
rate of ICC for Maryland in this time period was 9.7 per 100,000. After further adjusting 
for county characteristics including percent minority, percent screened for cervical cancer 
in the last 3-years and median household income, the average annual adjusted statewide 
ICC incidence rate was 9.2 per 100,000. In the fully adjusted space-time cluster detection 
analysis several clusters of high and low incidence were detected. These included 3 
significant space-time clusters of high and 2 significant space-time clusters of low ICC 
incidence, most of which were found in fairly recent time periods, between 2009 and 
2012. Based on the detected clusters of both high and low ICC incidence we concluded 
that although rates in some counties have dramatically declined overtime there are some 
areas in Maryland where ICC still needs to be prioritized and addressed.  
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In chapter 3 as part of our assessment of the utilization of Pap testing among WLWH we 
observed that although a large proportion (79%) of women received Pap testing, 21% of 
women who were in care for 18 months or longer did not receive Pap testing during 
follow-up at JHH. Further, only 11% of women consistently received Pap testing at the 
recommended annual interval and some women (5%) were consistently under-screened 
i.e. they were consistently screened at intervals longer the recommended. WLWH 
observed to have a decreased likelihood of receiving a Pap test included older women, 
injection drug users, white women and those who had lived for a longer time with HIV. 
Only women with a prior abnormal Pap test result were observed to be significantly more 
likely to receive Pap testing and no association was observed with either CD4 cell count 
or type of health insurance. Results of our longitudinal examination of Pap testing among 
WLWH enrolled in care adds to the literature on ICC screening among WLWH and 
presents potential targets in an urban HIV care setting for closer monitoring and directed 
interventions to improve utilization.  
Finally, in chapter 4 we prospectively evaluated the determinants and risk conferred by 
prevalent type-specific cervical HPV infections on the subsequent acquisition of the same 
HPV types orally. Results of our evaluation indicate that women with a recent history of 
sexual activity with either a male or female partner as well as those who performed oral 
sex in the prior 6 months had an increased risk of developing incident type-specific oral 
HPV infections. A marginal association was observed for HIV and no association was 
observed with cervical HPV infection, age, alcohol or condom use during oral sex. 
Therefore, these results suggest that having a prevalent cervical HPV infection is not 
associated with an increased risk of acquiring the same HPV types orally. However, 
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based on the strong association observed for women with a recent history of sexual 
activity we concluded that sexual activity remains an important risk factor for acquiring 
oral HPV infections. 
 
IMPLICATIONS FOR ADDRESSING ICC AND FUTURE DIRECTIONS 
 
Spatial Epidemiology 
Our assessment of the space-time variation in ICC incidence directly addresses goal 2 
objective 4 of the ICC specific target in the state cancer control plan for Maryland [91]. 
Our findings indicate that even in recent periods the burden of ICC in Maryland in an 
uneven, there are significant clusters of high and low incidence rates. Clusters of lower 
than expected rates identified provide evidence supporting the impact of state and local 
efforts to address ICC. While the clusters of higher than expected rates suggest that in 
spite of the progress made over time, some counties have seen an increased ICC 
incidence rate. These findings can aid the state to prioritize and efficiently address ICC 
associated morbidity within the state through further investigations and the delivery of 
targeted interventions to clusters of high rates.  
This evaluation of a space-time variation in ICC incidence was conducted at the county 
level and as such could not explore potential heterogeneity in incidence rates that may be 
present at smaller geographic units such as at the census tract level within each county 
[112,51]. Future studies using smaller geographic units of aggregation are needed to 
better characterize the specific hot and cold spots of ICC incidence within Maryland. In 
addition, building upon the ecologic study design utilized in this research, further studies 
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of variation in ICC incidence can employ multilevel models in their assessment. 
Multilevel modeling would allow an examination of both the independent as well as the 
combined effects of contextual levels factors, which this research examined and 
individual level data, which were not incorporated into this analysis [148,149].  Such an 
approach would adequately model multiple factors at the individual and contextual level 
that underlie variation in incidence over time [148,150].   
ICC Screening Among WLWH 
ICC is highly preventable especially if women are consistently and appropriately 
screened according to guideline recommendations and as the life expectancy for people 
living with HIV continues to increase it is important that WLWH adhere to screening 
guidelines in order to mitigate their ICC risk. Results of our longitudinal evaluation of 
Pap test utilization among WLWH in primary care indicate that for a substantial 
proportion of WLWH, being engaged in care does not necessarily guarantee routine 
access to cervical Pap testing as is recommended. Significant determinants of Pap testing 
for WLWH observed in our study include socio-demographic factors and a prior 
abnormal Pap test result. These identified factors can be harnessed into interventions that 
promote adherence to routine Pap testing for WLWH in care. Such interventions may 
include an educational component that explains the importance of routine screening or 
may involve the delivery of prompts to either WLWH with the characteristics identified 
by this research or to their providers at the recommended interval about scheduling the 
Pap tests.  
This assessment of Pap testing among WLWH relied mainly on a comprehensive 
database of medical and pathology records for WLWH enrolled in primary care at JHH. 
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Thus, this research could not evaluate variables not routinely captured in medical records 
including factors such as personal barriers faced by WLWH to routine Pap testing. In 
order to examine the contribution of such factors to Pap test utilization by WLWH, future 
studies involving mixed methods approaches of both quantitative methods and qualitative 
interviews are warranted. Such studies may be illuminating about complex interplay of 
clinical, sociodemographic factors and personal barriers to routine Pap testing among 
WLWH [151,152].  
The neighborhood in which individuals live has been shown to influence their health care 
utilization through barriers such as the lack of proximity to a healthcare provider [153-
155]. Hence, future studies can also utilize methods of spatial epidemiology to assess if 
unscreened or underscreened WLWH cluster with specific geographic units. These 
methods can also be used to examine the role of neighborhood effects in promoting Pap 
testing among WLWH. 
Oral HPV Infection  
The strong association observed between sexual exposure and the incidence of type-
specific oral HPV infections further underscores the importance of the sexual mode of 
transmission in the etiology of oral HPV infections. While the lack of an association 
observed between prevalent type-specific cervical HPV infections and the incidence of 
oral HPV infections suggests that cervical HPV infections may not play a role in the 
etiology of oral HPV infections. Thus, in addressing the growing burden of HPV-
associated oropharyngeal cancers, it is important that prevention and control programs 
continue to prioritize and address sexual exposure to HPV infections. Such interventions 
may include promoting the consistent and correct use of physical barriers such as dental 
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dams and oral condoms during oral-genital contact in order to minimize exposure to HPV 
infections orally [156,144,143]. Further; although the HPV vaccine is currently not 
licensed for the prevention of oropharyngeal cancers, some studies suggest that the 
vaccine is protective against oral HPV infections [157,158]. Thus, increasing uptake of 
the HPV vaccine both at the national level and among high-risk groups could potentially 
decrease the risk of oral HPV infections either directly through primary protection or 
eventually through herd immunity, once appropriately high vaccination rates have been 
achieved.  
Our study was conducted in a population of HIV positive and high-risk HIV negative 
women enrolled at three study sites within the United States. Thus, our findings may not 
reflect the risk of oral HPV infection among women living in regions of the world where 
HPV prevalence is extremely high. Risk of oral HPV infection in such populations may 
be significantly higher than that observed for the population studied by this research. 
Future studies involving women living in high burden regions may further enhance the 
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